



**Press Release**

Wednesday, March 6, 2013



Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

BSE: 532531

NSE: STAR

---

## **AGILA RECEIVES US FDA APPROVAL FOR ZOLEDRONIC ACID INJECTION**

---

**March 6, 2013:** Agila Specialties Pvt. Ltd., a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received ANDA approval for ***Zoledronic Acid Injection 4 mg (base) / 5 mL, packaged in single dose vials.***

According to IMS data, the US market for Zoledronic Acid 5ML s approximately USD 520 Million.



The product is expected to be launched shortly.

**About Zoledronic:**

Zoledronic Acid is used to treat high blood calcium levels (hypercalcemia) that may occur with cancer. Zoledronic acid is also used with cancer chemotherapy to treat bone problems that may occur with multiple myeloma and other types of cancer (such as breast, lung) that have spread to the bones

**About Agila Specialties**

Agila, Specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 9 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.



## **About Strides Arcolab**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at [www.stridesarco.com](http://www.stridesarco.com).

For further information, please contact:

| <b><u>Strides</u></b>                                                              | <b><u>PR Consultancy</u></b>                                                                                        |
|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Mr. V.S. Iyer, CEO - Agila<br>+91 80 6784 0111                                     | Corporate Voice   Weber Shandwick                                                                                   |
| Mr. Ajay Singh : +91 80 6784 0813<br>Mr. Kannan N : +91 98450 54745<br>(Investors) | Mahesh Nair,<br>+91 9880376648<br><a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a>    |
|                                                                                    | Kaveri Mandanna,<br>+91 90089 59697<br><a href="mailto:kaveri@corvoshandwick.co.in">kaveri@corvoshandwick.co.in</a> |

